Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) said it was “reported” after the market value evaporated more than 23 billion yuan in seven trading days.
On the afternoon of April 20, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) held a public media briefing. The company’s executives responded to five hot issues of public opinion, including clinical research, adverse reactions and contraindications of Lianhua Qingwen Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) board secretary Wu Rui said that he would continue to track the development of the situation. For some acts of slandering the company and publishing false information, the company has retained evidence and reported to relevant departments, and will safeguard its legitimate rights and interests through legal means.
however, “clarification” and “report” cannot prevent the funds from leaving. Yesterday, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) shares closed at 29.27 yuan, down 9.69%, with a cumulative decline of more than 30% in the last seven trading days
Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) response to five hot issues
Wu Lianrui responded to the hot issues on the prevention of plague and clinical adverse reactions in the media. Wu Rui also said that at present, the company’s scientific research, production and operation are normal.
\u3000\u3000 7
hot spot I: the research and development process of Lianhua Qingwen is only 15 days
The company said that the “research and development process of Lianhua Qingwen is only 15 days” reported in the media article was inconsistent with the facts. Lianhua Qingwen is an innovative application of collateral disease theory to epidemic prevention and control. The founder of the company has been committed to collateral disease research for 40 years. He has built a collateral disease theoretical system for the first time in the history of the development of traditional Chinese medicine and established a new discipline of collateral disease of traditional Chinese medicine. The leader of the company’s scientific research team has applied collateral disease theory to lung diseases for the first time, discussed the occurrence and development law of pulmonary collateral diseases, and gathered three famous prescriptions for the prevention and control of epidemic diseases of traditional Chinese medicine for 2000 to become the prescription of Lianhua Qingwen, And add Patchouli fragrance to protect the spleen and stomach and Rhodiola to improve immunity and healthy qi.
The innovative research of compound Chinese medicine requires the inheritance of the essence of Chinese medicine and the complete process of “theoretical innovation clinical practice pre clinical research clinical research new drug approval”. In February 2003, SARS broke out in Guangzhou, China. Both influenza and SARS belong to the category of “plague” of TCM. They have similar symptoms. During the follow-up research and development, the research team of the company will carry out new drug research for two indications of influenza and SARS, and complete the influenza, SARS efficacy study and toxicology research in May 2003, and declare clinical approval.
In May 2003, in order to promote the listing of drugs for the prevention, diagnosis and treatment of SARS as soon as possible, the State Food and Drug Administration issued the notice on matters related to the rapid approval of drugs for the prevention and treatment of SARS and the basic technical requirements for the research of drugs for the prevention and treatment of SARS, opening up a “green channel” to speed up the approval.
In June 2003, the company obtained clinical approval of Lianhua Qingwen for influenza treatment (approval number: 2003L02071) and Lianhua Qingwen treatment SARS clinical approval (approval number: 2003L02292). The company actively carried out preparations after approving clinical approvals, but in the process, because of the reduction of clinical cases in SARS, the clinical trials of influenza 2 and 3 were only carried out in clinical research.
In February 2004, Lianhua Qingwen applied for production.
In May 9, 2004, it was approved by the State Food and drug administration to be listed for the treatment of influenza virus (Z20040063).
The R & D process of Lianhua Qingwen new drug is the result of the rapid approval of the state in the special epidemic period and the joint efforts of R & D personnel, which is in line with the new drug R & D procedures of the national drug supervision department.
\u3000\u3000 2
hot spot 2: has Lianhua Qingwen ever carried out a double-blind study
There has been no double-blind study on Lianhua Qingwen, which is concerned by investors. The company said that randomized double-blind multicenter, randomized grouping multicenter and real-world research are all drug clinical evaluation methods recognized by the Xi’An International Medical Investment Company Limited(000516) community. Any of these research methods can be adopted for different diseases, different situations and different stages. The results are of scientific value. Lianhua Qingwen has been developed and listed for nearly 20 years. It is one of the most innovative traditional Chinese medicines in clinical evaluation research in China.
\u3000\u3000 3
hot spot 3: Lianhua Qingwen is the recommended drug for covid-19
The company said that when promoting Lianhua Qingwen, it has been promoting the market in strict accordance with the indications approved by the State Food and drug administration.
In April 2020, the State Drug Administration approved that the function of Lianhua Qingwen could be increased in the routine treatment of New Coronavirus pneumonia, and it could be used for fever, cough and fatigue caused by light and ordinary type.
After the outbreak of China’s COVID-19 epidemic, in January 27, 2020, the national health and Health Committee’s office and the office of the State Administration of traditional Chinese medicine jointly issued the New Coronavirus pneumonia diagnosis and treatment plan (trial version fourth). After the release of the New Coronavirus pneumonia diagnosis and treatment plan (Trial fifth / six / seven / 8 edition), Lian Huaqing’s disease continued to be recommended as a recommended medicine during the medical observation period. In March 14, 2022, the “New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth)”, in addition to the Lianhua Qingwen continue to be listed as the recommended treatment for Chinese medicine in the medical observation period, it is also classified as the recommended light and general recommendation in the clinical treatment period.
\u3000\u3000 4
hot spot 4: the instructions of Lianhua Qingwen are not clear about adverse reactions
According to some reports, the description of adverse reactions and contraindications in the drug Manual of Lianhua Qingwen has been unclear. The company said that in March 2019, the company had proposed amendments to the drug regulatory authorities on the “adverse reactions” and “contraindications” in the instructions of Lianhua Qingwen capsule in accordance with the provisions of the measures for the administration of drug registration and the guiding principles for the writing of over-the-counter instructions of Chinese patent drugs. The [adverse reaction] is revised to “the following gastrointestinal adverse reactions such as nausea, vomiting, abdominal pain, diarrhea, abdominal distension, nausea, rash, pruritus, dry mouth, dizziness, etc. can be seen in the post marketing monitoring data”, and the [taboo] is revised to “avoid taking for those who are allergic to this product and its components”.
The company said that Lianhua Qingwen, a Chinese patent medicine that has been on the market for nearly 20 years, has good safety. According to the data of the national adverse drug reaction monitoring system, the incidence of adverse reactions belongs to the “very rare” level recommended and defined by Xi’An International Medical Investment Company Limited(000516) scientific organization committee (CIOMS).
\u3000\u3000 5
hot spot 5: does the company publicly say “who ‘recommends’ Lianhua Qingwen”
According to the company’s self-examination, no one in the company has accepted the two media interviews mentioned in the video released by a microblog from the media, and has not said on any occasion that “who ‘recommends’ Lianhua Qingwen”.
The World Health Organization recently issued the report of the WHO expert evaluation meeting on the treatment of covid-19 pneumonia with traditional Chinese medicine (hereinafter referred to as the “evaluation report”), which clearly affirmed the effectiveness and safety of traditional Chinese medicine in the treatment of covid-19 pneumonia and encouraged WHO Member States to consider the possibility of using traditional Chinese medicine in the treatment of covid-19 pneumonia within their health care system and regulatory framework.
The above report recognizes the efficacy of traditional Chinese medicine including Lianhua Qingwen for covid-19 pneumonia. The company did not say on any occasion that “who ‘recommends’ Lianhua Qingwen”.
At the same time, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) said that the company will continue to track the development of the situation. For some acts of slandering the company and publishing false information, the company has retained evidence and reported to relevant departments, and will safeguard its legitimate rights and interests through legal means.
funds fled for days
Yesterday, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) share price continued to fall in large quantities, hitting the limit several times during the session, and finally closed at 29.27 yuan, down 9.69%, with a turnover rate of 10.47%, a turnover of 1.4401 million hands and a turnover of 4.353 billion yuan.
After the closing, the top five securities of Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) due to the deviation value of daily decline of 7% were listed on the dragon and tiger list. This is the fourth time that the company has been listed in nearly five trading days.
Public trading information shows that Shenzhen Stock connect occupies a buy one and sell one seat, with a net purchase of about 103 million yuan throughout the day. Other trading seats in the top five are almost reserved by “Lhasa tiantuan”. In addition, this is also the first time that no institutional seats have been sold wantonly in the company’s last four Dragon and tiger list information.
sort out Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) recent transaction information
On April 19, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) fell by the limit. After opening, it rebounded and closed slightly red. It had fallen by the limit for two consecutive days. After hours data showed that the four institutions sold a total of 305 million yuan, and Shenzhen Stock connect sold 399 million yuan and bought 177 million yuan.
On April 15, the data of the after hours dragon and tiger list showed that Guotai Junan Securities Co.Ltd(601211) Shanghai Branch sold nearly 500 million yuan, China International Capital Corporation Limited(601995) Shanghai Branch sold 200 million yuan and one institution sold 70.12 million yuan.
On April 14, a total of 579 million yuan was purchased in the first five buying business departments and 418 million yuan was sold in the first five selling business departments. On the same day, three special seats for institutions appeared, that is, selling two, selling three and selling four, with a total net sales of 139 million yuan.
It can be seen that within the above three trading days, the institutions resolutely fled, and the seats of listed institutions sold a total of 514 million yuan.
It is worth mentioning that this year, a total of 10 securities companies have rated Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) as overweight or buying, of which Huatai Securities Co.Ltd(601688) , with the highest target price, is only 33.01 yuan.
\u3000\u3000
